Accelerating CGT with Plug-and-Play Viral Vectors

Overview

With a surge in demand for high-quality clinic-ready viral vectors and the increase in cell and gene therapies gaining more popularity, we see a rising need for developers to find ways to accelerate their development process. Standardized plug-and-play manufacturing platforms could revolutionize viral vector production by effectively expediting product development timelines while being flexible enough to account for each products specific requirements.

Key Takeaways

• How templated platforms can get products to GMP in half the time

• Establishing platform processes

• How a global manufacturing partner can help ensure commercialization success